KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash & Current Investments (2017 - 2025)

Amneal Pharmaceuticals has reported Cash & Current Investments over the past 9 years, most recently at $28.8 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $28.8 million for Q4 2025, up 265.09% from a year ago — trailing twelve months through Dec 2025 was $28.8 million (up 265.09% YoY), and the annual figure for FY2025 was $28.8 million, up 265.09%.
  • Cash & Current Investments for Q4 2025 was $28.8 million at Amneal Pharmaceuticals, down from $34.7 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for AMRX hit a ceiling of $452.1 million in Q1 2021 and a floor of $4.3 million in Q3 2024.
  • Median Cash & Current Investments over the past 5 years was $17.5 million (2021), compared with a mean of $67.2 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 98.66% in 2022 and later soared 2284.21% in 2023.
  • Amneal Pharmaceuticals' Cash & Current Investments stood at $8.9 million in 2021, then skyrocketed by 190.27% to $26.0 million in 2022, then tumbled by 70.88% to $7.6 million in 2023, then grew by 4.43% to $7.9 million in 2024, then surged by 265.09% to $28.8 million in 2025.
  • The last three reported values for Cash & Current Investments were $28.8 million (Q4 2025), $34.7 million (Q3 2025), and $71.5 million (Q2 2025) per Business Quant data.